

Transitioning from IVF practice to restorative reproductive medicine.

Tadeusz Wasilewski

NaProedica

Białystok

Białystok



Cathedral
- Divine Mercy town

Medical University in Branicki Palace
- town of the first in vitro in Poland






Supraśl



Thank You Phil



Suprasl Poland

Reproductive medicine today


- **Infertility as a family, social and clinical problem**
- **Assisted Reproductive Technology (ART) as a response of medicine**
- **In vitro fertilization - embryo transfer**

Medical complications of in vitro

- **Ovarian hyperstimulation syndrome**
- **Multiple pregnancies**
- **Reduced health rates in children**

Multiple pregnancies (30%)

- Prematurity
- Low birth weight
- Increased perinatal mortality



Reduced health rates in children

Hansen M, Bower C, Milne E, de Klerk N, J Kurinczuk. Assisted reproductive technologies and the risk of birth defects – a systematic review. *Human Reproduction* 2005, 20(2),328-338

Human Reproduction Vol.20, No.2 pp.328-338, 2005
Advance Access publication November 26, 2004

doi:10.1093/humrep/dki593

Assisted reproductive technologies and the risk of birth defects—a systematic review

Michèle Hansen^{1,3}, Carol Bower¹, Elizabeth Milne¹, Nicholas de Klerk¹ and Jennifer J. Kurinczuk²

¹Centre for Child Health Research, The University of Western Australia Telethon Institute for Child Health Research, West Perth, Western Australia 6872, Australia and ²The National Perinatal Epidemiology Unit, University of Oxford, OX3 7LF, UK

³To whom correspondence should be addressed at: Telethon Institute for Child Health Research, PO Box 855, West Perth, Western Australia 6872. E-mail: michele@ichr.uwa.edu.au

BACKGROUND: The risk of birth defects in infants born following assisted reproductive technology (ART) treatment is a controversial question. Most publications examining the prevalence of birth defects in ICSI and IVF infants compared to spontaneously conceived infants have serious methodological limitations; despite this, most researchers have concluded that there is no increased risk. **METHODS:** We carried out a systematic review to identify all papers published by March 2003 with data relating to the prevalence of birth defects in infants conceived following IVF and/or ICSI compared with spontaneously conceived infants. Independent expert reviewers used criteria defined *a priori* to determine whether studies were suitable for inclusion in a meta-analysis. Fixed effects meta-analysis was performed for all studies and reviewer-selected studies. **RESULTS:** Twenty-five studies were identified for review. Two-thirds of these showed a 25% or greater increased risk of birth defects in ART infants. The results of meta-analyses of the seven reviewer-selected studies and of all 25 studies suggest a statistically significant 30–40% increased risk of birth defects associated with ART. **CONCLUSIONS:** Pooled results from all suitable published studies suggest that children born following ART are at increased risk of birth defects compared with spontaneous conceptions. This information should be made available to couples seeking ART treatment.

Key words: assisted reproductive technology; congenital malformations; IVF; meta-analysis; systematic review

Conclusion:

Risk of congenital defects associated with ART increases by 30 – 40%

Radical experiment on the genome



Ethical aspects of in vitro

Life not for every child

- selection
- cryopreservation
- preimplantation diagnostics
- embryoreduction



View of ESHRE

According to ESHRE (European Society of Human Reproduction and Embryology) recommendations treatment of infertility should result in birth of a **healthy child**.

Lambert RD. Safety issues in assisted reproductive technology: aetiology of health problems in singleton ART babies. Hum Reprod. **2003** Oct;18:1987-91.

New views

Physicians and biomedical researchers must be sufficiently proficient to find alternatives or to develop new ethically acceptable medical solutions **to prevent iatrogenic problems**

Human Reproduction Vol.17, No.12 pp. 3011–3015, 2002

Safety issues in assisted reproduction technology

The children of assisted reproduction confront the responsible conduct of assisted reproductive technologies

Raymond D.Lambert

The Declaration of Helsinki

‘It is the duty of the physician in medical research to protect the life, health, privacy, and dignity of the human subjects.’ (Article 10).

Work in the IVF Clinic

1993 - 2007

In vitro - life & death



Goodbye in vitro ...

Where is
my
family?

Where are
my sisters
and brothers

Where is

How long
do I have to
stay in the
freezer?

Who is my
grand-
mother?

?

Who is my
father?

Who is my
mother?

Embryo is my little patient

NaProMedica – place of realisation

NaProMedica



Preliminary data


- first two years of work

Objective – retrospective analysis of efficacy of treatment with natural methods in couples diagnosed with infertility

Patients & Methods – 412 couples diagnosed and treated in NaProMedica (Białystok, Poland) from January 2009 to November 2010 (more than one visit). Standard diagnostic procedures & CrMS (at least 3 months) & natural procreative support

Patients characteristics

our patients come from all over Poland



& from

Germany

UK

Ukraine


Belarus

Patients characteristics (n=412)


	Female	Male
Age, years mean \pm SD	33.7 \pm 4.3	35.7 \pm 6.0
(95% CI)	(33.3 – 34.1)	(35.1 – 36.3)
IQR	31- 37	31- 38

Female age sub-groups



25 – 29 y	30 – 35 y	36 – 39 y	40 – 47 y
N = 67	N = 216	N = 83	N = 46
27.9 ± 1.1	32.5 ± 1.7	37.3 ± 1.0	41.6 ± 1.9




History of in vitro & IUI



11.65%



29.37%




Time of Infertility

Time	Mean±SD	95% CI	Median	Range
Before first visit (years)	4.9 ± 3.3	4.6 – 5.2	4	2 - 21


Time of treatment - in months

Time	Mean±SD	95% CI	Median	Range
In NaProMedica (months)	8.5 ± 6.3 (5.5)	7.9 – 9.1	8	2 -27
I group Positive TEST	6.6 ± 5.3	5.4 – 7.9	5	2 -24
II group Negative TEST (Test t; p=0.007)	8.9 ± 6.4	8.2 – 9.5	8	2- 27

70 / 412 – 16.99%




Positive TEST vs. Female Age Factor



Chi² Pearson p=0.07

The highest efficacy - moderate infertility duration

Years of infertility
in Positive Test Group



χ^2 Pearson 26.53 df = 3 p<0.0001


Preliminary data

- first two years of work

Results

- of total 412 couples 70 conceived (positive TESTS) (16.99 %)
- mean time of infertility – 4.9 ± 3.3 years
- mean time of the diagnostic procedures & treatment in NaProMedica - 8.5 ± 6.3 months


NaProMedica Team



Agnieszka Ostrowska, FCP
Agata Szadkowska, FCP
Marta Wiesławska, FCP
Ewa Rucińska, M.A.
Emilia Matejczuk, M.A.
Katarzyna Snitkowska, RN
Irena Depczyńska, RN
Katarzyna Gierasimiuk, RN
Monika Rainko, RN
Maria Łazewska, M.D.
Tadeusz Wasilewski, M.D.
Jolanta Wasilewska, M.D.
www.napromedica.pl

NaProMedica

Poland



**„Respect, protect, love and serve life,
every human life!”**

John Paul II - Evangelium vitae

